Myo-Inositol trispyrophosphate (hexasodium)

Myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP) . myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer[1][2][3].

Product Specifications

CAS Number

[23103-35-7]

Product Name Alternative

ITPP (hexasodium)

UNSPSC

12352005

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/myo-inositol-trispyrophosphate-hexasodium.html

Purity

95.0

Solubility

H2O : 25 mg/mL (ultrasonic)

Smiles

O=P1(O[C@]2([H])[C@@]3([H])[C@@](OP(OP(O3)(O[Na])=O)(O[Na])=O)([H])[C@]4([H])[C@@](OP(OP(O4)(O[Na])=O)(O[Na])=O)([H])[C@@]2([H])OP(O1)(O[Na])=O)O[Na]

Molecular Formula

C6H6Na6O21P6

Molecular Weight

737.88

References & Citations

[1]Raykov Z, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134 (11) :2572-82.|[2]Fylaktakidou KC, et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15 (6) :1605-8.|[3]Oknińska M, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP) -enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24 (3) :2272-2283.